
ã³ãããæ³šå°ã®äœæ³¢ãã¯ã¯ãã³æ¥çš®è ã®94ïŒ ã«è¡æ 圢æã®å段éã®ç°ç©ããããšã®ç ç©¶çµæ
å èšäºã¯ãã¡ã/Original article here
2é±éåã«International Journal of Vaccine Theory, Practice, and ResearchïŒä»¥äžIJVTPRïŒã«æ²èŒãããã€ã¿ãªã¢ã®ç ç©¶ã§ã泚å°ãããã»ãŒå šå¡ã« "ã³ããæ¥çš® "åŸã®ç°åžžãããããšãæããã«ãªããŸãããã¯ã¯ãã³æ¥çš®è ã®94ïŒ ã®è¡æ¶²ã«ãèµ€è¡çã®åéãšæ§ã ãªåœ¢ã倧ããã®ç²åãååšããŠããã
ãã®ç ç©¶ã¯ã2021幎3æã«éå§ãããŸãããç ç©¶è ãã¯ãæèŠéé¡åŸ®é¡ãçšããŠããã¡ã€ã¶ãŒ/ãã€ãªNTechãŸãã¯ã¢ããã®mRNA "ã¯ã¯ãã³ "ãæ³šå°ãããåŸãæ§ã ãªé害ã®ããã«ãžã§ãã³ãçäœèšºæã»ã³ã¿ãŒã«ç޹ä»ããã1,006人ã®è¡æ¶²è©Šæãåæããã
ãã®ç ç©¶ã®èè ã¯ã"ã¯ã¯ãã³ "ã¯å°ãªããšãSARS-CoV-2ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªãå«ãã§ãããšãããŠããããå®éšç泚å°ã®å€ãã®æšé²è ãå šãå«ãŸããŠããªããšäž»åŒµããç°ç©ãå«ãã§ããããšãç¥ãããŠããããšææããã"ãããã®ç°ç©æåã®äžã«ã¯ãLeeã(2022)ãæ¬èªã§ä»¥å瀺ããããã«éå±ç©ãå«ãŸããŠãããããã¯æã ã®çµæã§ã確èªãããŠããŸãã"
åæããã1,006äŸã®ãã¡ããã£ã58äŸ-å šäœã®5.77%ã«çžåœ-ããModernaãPfizerã®èª¿åè¬ã䜿ã£ãæåŸã®mRNA泚å°åŸã«ãé¡åŸ®é¡åæã§å®å šã«æ£åžžãªè¡æ¶²åãåããã 948人ïŒç ç©¶åå è ã®94ïŒ ïŒã®è¡æ¶²ã«ã¯ãmRNA泚å°ã®1ãµæåŸã«èµ€è¡çã®åéãšãç±æ¥ãäžæãªæ§ã ãªåœ¢ãšå€§ããã®ç²åã®ååšã確èªãããŸããã
12人ã®è¢«éšè ã«ã€ããŠãã¯ã¯ãã³æ¥çš®åã«åãæ¹æ³ã§è¡æ¶²ã調ã¹ããšãããè¡æ¶²åŠçååžã¯å®å šã«æ£åžžã§ãã£ããmRNA泚å°ã®æ¥çš®åŸã«èªããããå€åã¯ããããããã¯ã¯ãã³ããã®ãã®ã«ãããã®ã§ãããšããçããããã«åŒ·ãããã®ã§ããã
æã ã¯ãã±ãŒã¹ã·ãªãŒãºå šäœã®ä»£è¡šãšããŠéžã°ãã4ã€ã®èšåºäŸãå ±åãããè¡æ¶²äžã«æ€åºãããç²åã®æ£ç¢ºãªæ§è³ªãæããã«ããæããã«ããããåŒãèµ·ãããŠããåé¡ã«å¯Ÿããå¯èœãªè§£æ±ºçãç¹å®ããããã«ããããªãç ç©¶ãå¿ èŠã§ããã
ãã®è«æã«ã¯å€ãã®éèŠãªãã€ã³ããå«ãŸããŠãããã©ãããã€ã©ã€ãããéžã¶ã®ã¯é£ãããã以äžã«ããã€ãã®ãã€ã©ã€ãã玹ä»ããããã®è«æã¯ãæ£åŒãªç§åŠæè²ãåããŠããªã人ã§ã容æã«çè§£ã§ããããã«æžãããŠãããæéããããŠå šäœãèªã䟡å€ã¯ååã«ãããŸããããã«æ·±ãç¥ãããæ¹ã¯ãè«ææ«å°Ÿã®åèæç®ããåç §ãã ããã
ç ç©¶èè ãã¯ããè¡æ¶²äžã«å¥åŠãªçŸè±¡ãèŠããã1,006äŸã®ãã¡94.23ïŒ ã®è¡æ¶²ã®é¡åŸ®é¡æ€æ»ã§èŠã€ãã£ãç°åžžã®ç¯å²ãšçš®é¡ã説æããŠãã...ïŒãã®4äŸã¯ïŒæ«æ¢¢è¡ã®å€åã瀺ããå š948äŸã®ä»£è¡šäŸã§ããããšãã4äŸã®èšåºäŸã®åçãæ²èŒããŠããã
以äžã«ãããã®åçã®äžéšãæ²èŒããããæ·»ä»ã®èª¬æã¯èªæã§ããã






èå¯ãšçµè«ã®éšåã§ãèè ã¯ããæžããŠããã
èµ€è¡çã®åéã匷調ãããæèŠéã«ç¹ç¶ã®å€æ¥èªå·±çºå ç²åãæ€åºãããããããã®ç²åã®çºå ã¯ãé žçŽ ãå«ãèµ€è¡çå£ã®çºå ãããé¡èã«é«ãã£ãã
948人ã®çäŸã§ã¯ã管ç¶ãç¹ç¶ç¶ã®åœ¢æ ãèŠããããã°ãã°çµæ¶ç¶ãã©ã¡ã©ç¶ã®åœ¢æ ãèŠãããéåžžã«è€éã§ã¯ããããç°åžžãªè¡æ¶²ãµã³ãã«ãæã€ãã¹ãŠã®æ£è ã«ãããŠäžè²«ããŠåæ§ã®åœ¢æ ã瀺ããã
æã ã®çµæã¯ãLee ãïŒ2022ïŒã®çµæãšéåžžã«ãã䌌ãŠãããPfizer ã Moderna ããã® mRNA 泚å°ã®è¡æ¶²äžã®é屿§ã®ç°ç©ãããŒã¯ããããã«æèŠéé¡åŸ®é¡ãçšããæã ã®é©æ°çãªå¿çšãé€ãã°ãæã ã¯éåœã®å»åž«ãã¡ã®è¡æ¶²æ€æ»ãã¯ããã«å€§ããªãµã³ãã«ã§åçŸãããšèšãããããããªãã
ååã«æçœãšæãããã®ã¯ãã¬ããã£ãšã¢ã³ã¿ããªïŒMontanari & Gatti, 2016; Gatti & Montanari, 2012, 2017, 2018ïŒãçºèŠãããããªé žåã°ã©ãã§ã³ã«äŒŒãéå±ç²åãšããããä»ã®éå±ååç©ããããããmRNA "ã¯ã¯ãã³ "ã«ã¡ãŒã«ãŒãé©åœã«å ¥ãããã®ã®ã«ã¯ãã«ã«å«ãŸããŠããããšã§ããã
èšåºå»ãšããŠã®æã ã®çµéšã§ã¯ããããã®mRNA泚å°ã¯åŸæ¥ã®ãã¯ã¯ãã³ããšã¯å šãç°ãªãããã®ã¡ãŒã«ãŒã¯ã泚å°ã«äœãå ¥ã£ãŠããã®ãããªãå ¥ã£ãŠããã®ãã«ã€ããŠçœç¶ããå¿ èŠããããšæã ã¯èããŠããŸãã
çµè«ãšããŠãç§ãã¡ã®èšåºçµéšã§ã¯ã948äººã®æ£è ã®æ«æ¢¢è¡ãããã¡ã€ã«ã«èšé²ããããããªæ¥æ¿ãªå€åã¯ãéå»ã«ãããªãã¯ã¯ãã³ãæ¥çš®ããåŸã«ã芳å¯ãããããšã¯ãããŸãããéåžž2åç®ã®mRNAæ³šå ¥æã«ãå®å šãªæ£åžžç¶æ ãããæº¶è¡ãèµ€è¡çã®ç®ã«èŠããå å¡«ãšç©å±€ã巚倧ãªåéç°ç©æ§é ïŒãã®ããã€ãã¯ã°ã©ãã§ã³ãã¡ããªãŒã®è¶ æ§é ã«èŠããïŒã®åœ¢æã䌎ãç çç¶æ ãžçªç¶ç§»è¡ããããšã¯ãåäŸããããŸããã
ç§ãã¡ã®çµéšäžããŸãå°éå®¶ãšããŠã®å ±éã®èŠè§£ãšããŠãmRNA泚å°ãåãã人ã®è¡æ¶²äžã«å€§éã®ç²åãååšããããšã¯ãç¹ã«æ¯çްè¡ç®¡ã®ã¬ãã«ã§ã¯æ£åžžãªè¡æµãšã¯çžå®¹ããªããã®ã§ããã